Overview

Safety and Immunogenicity of MSB11455 in Healthy Participants

Status:
Completed
Trial end date:
2018-09-22
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Fresenius Kabi SwissBioSim GmbH
Merck KGaA